Argo Biopharma

News

Novartis is paying $160m upfront to activate an expanded R&D alliance with China's Argo Biopharma covering multiple cardiovascular disease drugs.

News

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.